Amphiphilic aminoglycoside connexin hemichannel inhibitors
US-2021163521-A1 · Jun 3, 2021 · US
Amphiphilic kanamycin compositions and methods
US12110310B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12110310-B2 |
| Application number | US-202117157752-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jan 25, 2021 |
| Priority date | Jan 23, 2020 |
| Publication date | Oct 8, 2024 |
| Grant date | Oct 8, 2024 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present relates to novel bioactive amphiphilic kanamycin compounds having the general formula of: where R may be a C 4 to C 20 branched or straight chained alkyl group or a substituted or unsubstituted aryl group. Also provided are methods of synthesizing and methods of using the compounds of the present invention. The compounds of the present invention are useful in treating and preventing various fungal and bacterial diseases.
First claim
Opening claim text (preview).
What is claimed is: 1. An amphiphilic kanamycin compound, or salt thereof, having the formula: wherein R is an unsubstituted C 17 -alkyl. 2. A method of synthesizing the amphiphilic kanamycin compound of claim 1 , the method comprising: reacting kanamycin sulfate having the formula: with K 2 CO 3 and a compound having the formula: wherein R is an unsubstituted C 17 -alkyl. 3. A method of treating an infection, the method comprising: administering to a host in need thereof an effective amount of an amphiphilic kanamycin compound, or salt thereof, having the formula: wherein R is an unsubstituted C 17 -alkyl. 4. The method of claim 3 , wherein the infection is a bacterial infection. 5. The method of claim 3 , wherein the infection is a fungal infection. 6. The method of claim 3 , wherein the infection is a fungal and bacterial infection.
Assignees
Inventors
Classifications
having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins · CPC title
attached to non-adjacent ring carbon atoms of the cyclohexane rings, e.g. kanamycins, tobramycin, nebramycin, gentamicin A2 · CPC title
- A61P31/04Primary
Antibacterial agents · CPC title
- C07H15/23Primary
with only two saccharide radicals in the molecule, e.g. ambutyrosin, butyrosin, xylostatin, ribostamycin · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12110310B2 cover?
- The present relates to novel bioactive amphiphilic kanamycin compounds having the general formula of: where R may be a C 4 to C 20 branched or straight chained alkyl group or a substituted or unsubstituted aryl group. Also provided are methods of synthesizing and methods of using the compounds of the present invention. The compounds of the present invention are usef…
- Who is the assignee on this patent?
- Chang Cheng Wei Tom, Takemoto Jon Y, Univ Utah State
- What technology area does this patent fall under?
- Primary CPC classification A61P31/04. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Oct 08 2024 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 4 related publications on this page (citations in our corpus or others sharing the same primary CPC).